// App-Quantinova.ai

PB0825 : Burden of Illness in Patients With von Willebrand Disease Receiving Prophylaxis Versus Potential Prophylaxis-Eligible Patients: A Post-Hoc Analysis of A European Socioeconomic Study

Researchers

Presenter

  • P. Du

Principal Investigators

  • G. Morgan

  • F. Truong Berthoz

  • N. Kemenyash

  • S. Sun

Medical Centers

  • Takeda Development Center Americas, Inc., Cambridge, MA, Cambridge, Massachusetts, United States

  • HCD Economics, Daresbury, United Kingdom

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved